By Sabela Ojea IGC Pharma said its Alzheimer's disease drug candidate TGR-63 demonstrated enhanced memory function in preclinical studies. The pharmaceutical.
IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 796,900 shares, a drop of 10.1% from the September 15th total of 886,000 shares. Currently, 1.9% of the company’s shares are sold short. […]
IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 850,600 shares, a growth of 7.0% from the August 15th total of 795,000 shares. Based on an average daily trading volume, of 207,200 shares, the short-interest […]
IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.34. IGC Pharma shares last traded at $0.31, with a volume of 84,859 shares. IGC Pharma Stock Performance The stock […]